×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
NASDAQ:RARE

Ultragenyx Pharmaceutical Price Target, Predictions & Analyst Ratings

$63.38
-0.42 (-0.66%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$63.04
$66.06
50-Day Range
$45.80
$72.29
52-Week Range
$45.20
$104.38
Volume
611,563 shs
Average Volume
493,608 shs
Market Capitalization
$4.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$109.75

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$109.75
73.16% Upside
High Prediction$142.00
Average Prediction$109.75
Low Prediction$73.00
TypeCurrent
7/7/21 to 7/7/22
1 Month Ago
6/7/21 to 6/7/22
3 Months Ago
4/8/21 to 4/8/22
1 Year Ago
7/7/20 to 7/7/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$109.75$111.29$123.81$153.46
Predicted Upside73.16% Upside52.06% Upside42.78% Upside15.81% Upside
Get Ultragenyx Pharmaceutical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.


RARE Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RARE Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ultragenyx Pharmaceutical Stock vs. The Competition

TypeUltragenyx PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
2.58
2.72
2.51
Consensus RatingModerate BuyBuyBuy
Predicted Upside73.16% Upside461.71% Upside31.93% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
776
79.10%
Underperform Votes
205
20.90%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
839
69.05%
Avg. Underperform Votes
376
30.95%

Historical Ultragenyx Pharmaceutical Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/1/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$176.00 ➝ $142.00+138.02%
5/24/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$139.00 ➝ $101.00+117.91%
5/18/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$170.00 ➝ $135.00+183.02%
5/6/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$124.00 ➝ $99.00+65.19%
3/16/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$99.00 ➝ $105.00+64.86%
2/11/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$120.00 ➝ $118.00+57.25%
2/11/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$132.00+84.87%
10/5/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
9/30/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Zhang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$106.00+23.08%
8/19/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$73.00-10.93%
8/3/2021Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$106.00 ➝ $91.00+12.57%
8/3/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$178.00 ➝ $141.00+74.42%
7/15/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$84.74
6/29/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$162.00+68.05%
5/6/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$160.00 ➝ $151.00+33.79%
5/5/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$144.00+35.72%
1/11/2021Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$110.00 ➝ $165.00+9.57%
10/28/2020Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$88.00 ➝ $110.00+13.58%
7/1/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joon Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$82.00 ➝ $88.00+4.85%
1/2/2020Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
12/18/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$70.00+53.11%
(Data available from 7/7/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Ultragenyx Pharmaceutical Price Target - Frequently Asked Questions

What is Ultragenyx Pharmaceutical's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Ultragenyx Pharmaceutical stock is Moderate Buy based on the current 1 sell rating, 3 hold ratings and 8 buy ratings for RARE. The average twelve-month price prediction for Ultragenyx Pharmaceutical is $109.75 with a high price target of $142.00 and a low price target of $73.00. Learn more on RARE's analyst rating history.

Do Wall Street analysts like Ultragenyx Pharmaceutical more than its competitors?

Analysts like Ultragenyx Pharmaceutical stock less than the stock of other Medical companies. The consensus rating for Ultragenyx Pharmaceutical is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how RARE compares to other companies.

Do MarketBeat users like Ultragenyx Pharmaceutical more than its competitors?

MarketBeat users like Ultragenyx Pharmaceutical stock more than the stock of other Medical companies. 79.10% of MarketBeat users gave Ultragenyx Pharmaceutical an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does Ultragenyx Pharmaceutical's stock price have much upside?

According to analysts, Ultragenyx Pharmaceutical's stock has a predicted upside of 56.50% based on their 12-month price targets.

What analysts cover Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has been rated by Cowen, Cowen, Piper Sandler, Stifel Nicolaus, and The Goldman Sachs Group in the past 90 days.

This page (NASDAQ:RARE) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.